GLP-1RA Cardiovascular Benefits: AI Analysis of Patient Data
Summary of the Statistical Analysis Methods Used in the study
this text details the statistical methods used to analyze data from the LEADER and SUSTAIN-6 trials to understand treatment response to GLP-1 receptor agonists in type 2 diabetes. Here’s a breakdown:
1. Data Partitioning:
* Training Set: 70% of participants from both LEADER and SUSTAIN-6 were combined to train the models.
* Test Set: The remaining 30% from each trial were combined to test the models.
2. Identifying Treatment Response Subgroups (PRISM Framework):
* PRISM (Patient Response Identifiers for Stratified Medicine): A multi-step machine learning (ML) approach was used.
* Step 1: Developed a multivariable risk model for the outcome without treatment (control conditions).
* Step 2: Used interaction modeling with regularized regression (elastic net) to identify baseline factors that modify treatment benefit.
3. Overall Clinical Benefit Assessment:
* Cox Proportional Hazard Model: Used to test the overall clinical benefit of treatment across the combined LEADER + SUSTAIN-6 cohort. This model included a variable to account for which trial the participant was from.
* Sensitivity Analyses: Performed to address potential imbalances in randomization within identified subgroups (based on Standardized Mean Difference (SMD) > 0.1 and p < 0.05).
4. Estimating Treatment Affect:
* Predicted Survival Probability & NNT-ARR: Calculated at 3.6 years (median follow-up of the original trials).
* NNT-ARR (Number Needed to Treat based on Absolute Risk Reduction): Estimated using methods by Austin et al. (references 19 & 20).
* Bootstrapping: Used to calculate confidence intervals and standard errors for ARR (1000 samples with replacement).
* Quantitative Scale Interactions: Tested using Gail and Simon methods (reference 21).
5. Variables Considered for Transferability & Heterogeneity:
A wide range of baseline characteristics were examined to understand how treatment response might vary:
* Demographics: Age, sex, BMI
* Diabetes History: Duration of diabetes, baseline HbA1c
* Cardiovascular History: History of CVD, HF, MI, stroke, peripheral artery disease, hypertension
* Kidney Function: eGFR
* Medications: Use of metformin, sulphonylureas, thiazolidinediones, DPP4 inhibitors, RAS blockers, calcium channel blockers, beta blockers, diuretics, antiplatelet treatment, and statins.
* Urinary Albumin/creatinine Ratio (UACR): Used in LEADER analysis only (due to missing data in SUSTAIN-6).
6. External Validation:
* The same analytical approach was used for external validation, referencing original study populations (reference 10).
In essence, the study employed a elegant machine learning approach (PRISM) combined with customary survival analysis techniques to identify subgroups of patients who might benefit differently from GLP-1 receptor agonist treatment. They also focused on quantifying the magnitude of these differences and assessing the robustness of thier findings.